Nevirapine Vocate

Nevirapine, the active ingredient in Nevirapine Vocate, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the management of HIV-1 infection in adults, adolescents and for prevention of mother‑to‑child transmission.

GNH USA supplies Nevirapine Vocate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution with appropriate documentation to meet regulatory requirements in each market.

Nevirapine is indicated for HIV‑1 infection, acting as part of combination antiretroviral therapy.

HIV-1 infection (adults): Used in combination regimens to suppress viral replication. HIV-1 infection (adolescents ≥12 years): Provides viral suppression when combined with other antiretrovirals. Prevention of mother‑to‑child transmission of HIV-1: Used in pregnant women as part of a regimen to reduce transmission risk.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hepatic failure - Hypersensitivity reactions including severe skin eruptions

Nevirapine requires careful monitoring and patient education to minimize risks. - Liver function monitoring: assess baseline and periodic liver enzymes. - Skin reactions: observe for rash and discontinue if severe or progressive. - Pregnancy considerations: evaluate risk‑benefit ratio before use. - Drug interactions: review concomitant medications for potential interactions. - Store at room temperature: keep in the original container, protect from moisture and heat.

Nevirapine can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may increase nevirapine concentrations. - St. John’s wort: may reduce nevirapine exposure. - Azole antifungals (e.g., ketoconazole): may increase toxicity risk.

Moderate Interactions (Monitor Closely): - Efavirenz: may add central nervous system effects. - Tetracyclines: may increase hepatotoxic potential.